Fig. 3From: Evaluation of the pharmacokinetics, dosimetry, and therapeutic efficacy for the α-particle-emitting transarterial radioembolization (αTARE) agent [225Ac]Ac-DOTA-TDA-Lipiodol® against hepatic tumorsKaplan–Meier survival plots of tumor-bearing A female and B male mice receiving the following treatments: (1) PBS (20 μL) (2) Lipiodol® alone (20 μL) or (3) [225Ac]Ac-DOTA-TDA-Lipiodol® (37 kBq, 20 μL)Back to article page